Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 25NIH 5NETWORK 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 106Other hematologic neoplasm 40Lymphoid 23Plasma cell 13Classical hematology 10Thoracic 7Gastrointestinal 6Breast 6Gynecologic 4Genitourinary 4Dermatologic 3CNS 3Head & Neck 2Endocrine 2Sarcoma 1Other solid neoplasm 1Other neoplasm 1NET 1

Conditions

Precancerous Conditions 20Neoplasms 9Advanced Malignant Neoplasm 9Keratosis, Actinic 8Skin Diseases 5Keratosis 5Uterine Cervical Neoplasms 3Uterine Cervical Dysplasia 2Preleukemia 2Pathologic Processes 2Neoplasms by Site 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Leukemia 2Hormone Receptor Positive Malignant Neoplasm of Breast 2Hematologic Diseases 2Endometrial Neoplasms 2Carcinoma 2Breast Neoplasms 2Bone Marrow Diseases 2Biochemical Recurrence of Malignant Neoplasm of Prostate 2Uterine Prolapse 1Uterine Neoplasms 1Uterine Diseases 1Uterine Cervical Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Thrombocythemia, Essential 1Syndrome 1

Interventions

ruxolitinib 1CPI-0610 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Myeloproliferative Disorders × Other neoplasm × Clear all
NCT02158858 2026-06-04

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Constellation Pharmaceuticals

Phase 1/2 Completed
336 enrolled 61 charts
MyeloidOther hematologic neoplasmOther neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡